HOME >> BIOLOGY >> NEWS
First target for childhood malaria vaccine

The discovery of a malaria parasite protein that is associated with the severe childhood form of the disease could save the lives of many thousands of children in sub-Saharan Africa. Anja Jensen and colleagues, reporting in The Journal of Experimental Medicine, suggest that this protein could form the basis of a new vaccine against severe malaria.

The malaria-causing parasite Plasmodium falciparum, which is transmitted by mosquito bite, replicates in human red blood cells, which then burst causing life-threatening fever. Infected red blood cells display parasite proteins on their surface that help the parasite to survive in their human host and cause disease complications.

People who have grown up in regions where malaria is endemic usually develop protective antibodies to these parasite proteins, and symptoms in adults are mild compared with the severe disease seen in young children with no previous exposure. Previous work has indicated that the parasites causing severe disease express a set of proteins that are distinct from those produced by parasites that infect adults. But up to this point, no one had identified any of these proteins.

The authors developed a new method to compare for the first time the proteins that are expressed by two types of P. falciparum that cause severe childhood malaria and less severe adult infection, respectively. They identified one protein that is expressed on the surface of red blood cells during severe childhood malaria but not during adult infections. This protein causes infected red blood cells to stick inside blood vessels, preventing their removal in the spleen.

The study also found that this protein, unlike similar malaria proteins studied, does not vary between malaria parasites from East and West Africa, making it an ideal candidate for a universal vaccine to boost immunity to severe malaria in young children.


'"/>

Contact: Lynette Henry
henryn@rockefeller.edu
212-327-8575
Journal of Experimental Medicine
3-May-2004


Page: 1

Related biology news :

1. First glimpse of DNA binding to viral enzyme
2. First clinical study of new pediatric croup vaccine shows safety, tolerability in adults
3. 2nd media alert First Scientific Conference on Childhood Leukaemia
4. First International Scientific Conference on Childhood Leukaemia
5. First ever standards linking climate change, biodiversity and poverty seek global peer review
6. First genetic comparison of purebred domestic dogs produces surprises
7. First time in the U.S.: Saint Louis University tests third-generation vaccine against smallpox
8. First study of resveratrol dietary supplement finds effect on breast and prostate cancers unlikely
9. First flavors form a lasting impression
10. STN International launches Derwent World Patents Index First View
11. First DFG research conference in the USA

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/4/2019)... ... January 03, 2019 , ... Over the ... into their drug discovery research workflows with biology ranging from single cell-type spheroids ... of in vitro studies, they create several challenges that need to be overcome ...
(Date:12/27/2018)... FRANCISCO (PRWEB) , ... December 27, 2018 , ... ... annual Microbiome Conference at JPM as part of the JP Morgan 37th Annual ... innovative scientists and physicians, and members of the investment community. , Since ...
(Date:12/20/2018)... ... December 20, 2018 , ... Human Factors and product ... a new usability/observation room. This addition will help meet the increased industry demand ... delivery devices/combination products are safe and easy to use when released to the ...
Breaking Biology News(10 mins):
(Date:1/10/2019)... Fla. (PRWEB) , ... January ... ... Geometrical Implant Co, (SAGICO), an innovative spinal implant company, announced today that ... in San Francisco, California. The annual J.P. Morgan Healthcare Conference is ...
(Date:1/7/2019)... SEONGNAM, South Korea (PRWEB) , ... January 07, ... ... has completed Phase 1 clinical trials of its Parkinson's Disease drug candidate, code-named ... disease-modifying treatment of Parkinson's Disease. The trial took place in South Korea. ...
(Date:1/4/2019)... ... January 03, 2019 , ... Calidi Biotherapeutics, Inc., ... today announced the founding of a scientific and medical advisory board (SMAB). The ... leaders in the Immuno-Oncology field. The founding members of Calidi Biotherapeutics SMAB include ...
(Date:12/18/2018)... ... December 17, 2018 , ... ABCT ... emerging biosciences ventures invited to participate in the annual program. Twelve ventures will ... plans and a professional network. All startups receive an entrepreneur coach, access to ...
Breaking Biology Technology:
Cached News: